NO2776305T3 - - Google Patents

Info

Publication number
NO2776305T3
NO2776305T3 NO12790406A NO12790406A NO2776305T3 NO 2776305 T3 NO2776305 T3 NO 2776305T3 NO 12790406 A NO12790406 A NO 12790406A NO 12790406 A NO12790406 A NO 12790406A NO 2776305 T3 NO2776305 T3 NO 2776305T3
Authority
NO
Norway
Application number
NO12790406A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2776305T3 publication Critical patent/NO2776305T3/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
NO12790406A 2014-04-23 2012-11-06 NO2776305T3 (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461983152P 2014-04-23 2014-04-23

Publications (1)

Publication Number Publication Date
NO2776305T3 true NO2776305T3 (cs) 2018-01-27

Family

ID=53055121

Family Applications (1)

Application Number Title Priority Date Filing Date
NO12790406A NO2776305T3 (cs) 2014-04-23 2012-11-06

Country Status (38)

Country Link
US (5) US9908927B2 (cs)
EP (2) EP3366699A1 (cs)
JP (2) JP6523331B2 (cs)
KR (2) KR20190135546A (cs)
CN (2) CN111718424A (cs)
AR (1) AR100168A1 (cs)
AU (3) AU2015249649B2 (cs)
BR (1) BR112016024515B1 (cs)
CA (2) CA3184067A1 (cs)
CL (1) CL2016002683A1 (cs)
CR (1) CR20160516A (cs)
CY (1) CY1120281T1 (cs)
DK (1) DK3134430T3 (cs)
DO (1) DOP2016000284A (cs)
EC (1) ECSP16089579A (cs)
ES (1) ES2672368T3 (cs)
HR (1) HRP20180950T1 (cs)
HU (1) HUE038914T2 (cs)
IL (2) IL248244B (cs)
LT (1) LT3134430T (cs)
MA (2) MA39770A (cs)
MX (2) MX2016013858A (cs)
MY (1) MY181986A (cs)
NO (1) NO2776305T3 (cs)
PE (1) PE20170299A1 (cs)
PH (2) PH12020500377A1 (cs)
PL (1) PL3134430T3 (cs)
PT (1) PT3134430T (cs)
RS (1) RS57153B1 (cs)
RU (1) RU2699285C2 (cs)
SG (3) SG10201806465TA (cs)
SI (1) SI3134430T1 (cs)
SM (1) SMT201800286T1 (cs)
TR (1) TR201806912T4 (cs)
TW (2) TWI747178B (cs)
UA (1) UA118286C2 (cs)
UY (1) UY36095A (cs)
WO (1) WO2015164588A1 (cs)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016257000B2 (en) 2015-05-04 2020-05-14 Apogenix Ag Single-chain CD40-receptor agonist proteins
EP3364995B1 (en) 2015-10-23 2021-08-04 Apogenix AG Single-chain cd27-receptor agonist proteins
AU2016342420B2 (en) * 2015-10-23 2020-10-01 Apogenix Ag Single-chain LIGHT receptor agonist proteins
CA3002741A1 (en) * 2015-10-23 2017-04-27 Apogenix Ag Single-chain gitr-receptor agonist proteins
WO2017102010A1 (en) * 2015-12-17 2017-06-22 Biontech Rna Pharmaceuticals Gmbh Novel cytokine fusion proteins
JP7091248B2 (ja) 2016-03-01 2022-06-27 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイ 低減されたl-グルタミナーゼ活性および増強された安定性を有するl-アスパラギナーゼ変異体および融合タンパク質
US20190077870A1 (en) * 2016-03-16 2019-03-14 Merrimack Pharmaceuticals, Inc. Engineered trail for cancer therapy
US10501744B2 (en) 2016-05-04 2019-12-10 Indiana University Research And Technology Corporation Presentation of bioactive proteins
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Hdac抑制劑與pd-l1抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
AU2017283487A1 (en) * 2016-06-13 2018-11-22 Merrimack Pharmaceuticals, Inc. Methods for selecting and treating patients with a trail-based therapeutic or death receptor agonist
EP3360898A1 (en) 2017-02-14 2018-08-15 Boehringer Ingelheim International GmbH Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
CN111050784B (zh) * 2017-08-11 2024-03-19 伊利诺伊大学理事会 截短的豚鼠l-天冬酰胺酶变体及其使用方法
WO2019178433A1 (en) * 2018-03-15 2019-09-19 Abbvie Inc. Abbv-621 in combination with anti-cancer agents for the treatment of pancreatic cancer
WO2019178438A1 (en) * 2018-03-15 2019-09-19 Abbvie Inc. Abbv-621 in combination with anti-cancer agents for the treatment of cancer
CN115836084A (zh) 2020-05-15 2023-03-21 阿珀吉尼科斯股份公司 多特异性免疫调节剂
WO2022248662A1 (en) 2021-05-28 2022-12-01 Julius-Maximilians-Universität Würzburg Recombinant proteinaceous binding molecules
WO2023088876A1 (en) 2021-11-16 2023-05-25 Apogenix Ag Multi-specific immune modulators

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1226173A1 (en) 1999-10-07 2002-07-31 Maxygen Aps Single-chain antagonist polypeptides
DE19963859A1 (de) 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
CA2314199A1 (en) 2000-07-21 2002-01-21 Robert Simoneau C-chip
IL155812A0 (en) 2000-12-07 2003-12-23 Lilly Co Eli Glp-1 fusion proteins
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
AU2003234274A1 (en) 2002-04-26 2003-11-10 California Institute Of Technology D1-1 nucleic acids, polypeptides and related methods
DE102004014983A1 (de) 2004-03-26 2005-10-20 Univ Stuttgart Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung
US20060188498A1 (en) * 2005-02-18 2006-08-24 Genentech, Inc. Methods of using death receptor agonists and EGFR inhibitors
MX2007010484A (es) 2005-04-15 2007-10-15 Rappaport Family Inst For Res Moleculas y metodos para usarlas para tratar enfermedades asociadas con mcp-1/ccr2.
AU2006239851B2 (en) 2005-04-26 2011-06-16 Medimmune, Llc Modulation of antibody effector function by hinge domain engineering
EP1894940A1 (en) 2006-08-28 2008-03-05 Apogenix GmbH TNF superfamily fusion proteins
WO2009007120A2 (en) 2007-07-10 2009-01-15 Apogenix Gmbh Tnf superfamily collectin fusion proteins
PE20100092A1 (es) 2008-06-03 2010-03-12 Abbott Lab Inmunoglobulina con dominio variable dual y usos de la misma
US8450460B2 (en) * 2008-07-21 2013-05-28 Apogenix Gmbh Single-chain TNFSF fusion polypeptides
AU2009293545A1 (en) 2008-09-22 2010-03-25 Amgen Inc. Method of treatment
JP2012504969A (ja) * 2008-10-10 2012-03-01 アナフォア インコーポレイテッド Trail−r1及びtrail−r2に結合するポリペプチド
EP2829550B1 (en) 2009-01-09 2016-11-16 Apogenix AG Fusion proteins forming trimers
BRPI1006998A2 (pt) * 2009-01-23 2015-08-25 Biogen Idec Inc Polipeptídeos fc estabilizados com função efetora reduzida e métodos de uso
AU2010334974A1 (en) 2009-12-22 2012-07-12 Novartis Ag Tetravalent CD47-antibody constant region fusion protein for use in therapy
MX341119B (es) * 2010-04-13 2016-08-09 Medimmune Llc Estructuras multiméricas específicas para ligando inductor de apoptosis relacionada con el factor de necrosis tumoral r2 (trail).
CA2858806A1 (en) * 2011-12-23 2013-06-27 Innate Pharma Enzymatic conjugation of polypeptides
ES2924109T3 (es) 2012-07-18 2022-10-04 Apogenix Ag Composición que comprende una mezcla de isoformas de CD95-Fc

Also Published As

Publication number Publication date
IL248244B (en) 2020-03-31
JP6523331B2 (ja) 2019-05-29
KR20190135546A (ko) 2019-12-06
RU2699285C2 (ru) 2019-09-04
AR100168A1 (es) 2016-09-14
MA39770A (fr) 2015-10-29
HUE038914T2 (hu) 2018-12-28
PE20170299A1 (es) 2017-05-06
AU2018271369B2 (en) 2020-01-02
MX2016013858A (es) 2017-08-02
AU2018271369A1 (en) 2018-12-20
KR102079919B1 (ko) 2020-02-24
TW202024123A (zh) 2020-07-01
US20210040178A1 (en) 2021-02-11
RU2016145608A (ru) 2018-05-28
NZ725476A (en) 2023-09-29
ES2672368T3 (es) 2018-06-14
CA3184067A1 (en) 2015-10-29
JP2019162114A (ja) 2019-09-26
EP3134430A1 (en) 2017-03-01
SG11201608767XA (en) 2016-11-29
PH12020500377A1 (en) 2022-11-14
AU2015249649A1 (en) 2016-11-10
CL2016002683A1 (es) 2017-07-07
IL272612A (en) 2020-03-31
SG10201806465TA (en) 2018-08-30
CA2946402A1 (en) 2015-10-29
US20180222962A1 (en) 2018-08-09
PH12016502079A1 (en) 2016-12-19
CR20160516A (es) 2017-05-10
EP3134430B1 (en) 2018-03-21
MY181986A (en) 2021-01-18
TW201620928A (zh) 2016-06-16
PH12016502079B1 (en) 2016-12-19
MA45069A (fr) 2019-04-03
LT3134430T (lt) 2018-05-10
PL3134430T3 (pl) 2018-08-31
RU2016145608A3 (cs) 2018-12-26
CY1120281T1 (el) 2019-07-10
DK3134430T3 (en) 2018-05-22
US20240174731A1 (en) 2024-05-30
CA2946402C (en) 2023-02-28
PT3134430T (pt) 2018-04-20
AU2020202247A1 (en) 2020-04-23
BR112016024515A2 (pt) 2017-10-10
RS57153B1 (sr) 2018-07-31
TWI683825B (zh) 2020-02-01
JP6714751B2 (ja) 2020-06-24
HRP20180950T1 (hr) 2018-08-10
EP3366699A1 (en) 2018-08-29
IL248244A0 (en) 2016-11-30
DOP2016000284A (es) 2017-02-15
SG10202111785VA (en) 2021-12-30
AU2015249649B2 (en) 2018-10-04
CN111718424A (zh) 2020-09-29
UY36095A (es) 2015-10-30
SMT201800286T1 (it) 2018-07-17
TWI747178B (zh) 2021-11-21
US20250145688A1 (en) 2025-05-08
JP2017513503A (ja) 2017-06-01
MX2019013587A (es) 2020-01-13
WO2015164588A1 (en) 2015-10-29
US9908927B2 (en) 2018-03-06
CN106459221B (zh) 2020-09-01
SI3134430T1 (en) 2018-05-31
UA118286C2 (uk) 2018-12-26
BR112016024515B1 (pt) 2020-03-31
US20150337027A1 (en) 2015-11-26
ECSP16089579A (es) 2018-05-31
KR20170012257A (ko) 2017-02-02
TR201806912T4 (tr) 2018-06-21
CN106459221A (zh) 2017-02-22

Similar Documents

Publication Publication Date Title
BR112015001052A2 (cs)
BR112014017635A2 (cs)
BR112014017614A2 (cs)
BR112014019099A2 (cs)
BR112014019260A2 (cs)
BR112014017625A2 (cs)
BR112014017659A2 (cs)
BR112014017592A2 (cs)
BR112014017646A2 (cs)
BR112014017638A2 (cs)
BR112014017607A2 (cs)
BR112014017609A2 (cs)
BR112014017634A2 (cs)
BR112014017938A2 (cs)
BR112014017644A2 (cs)
NO2776305T3 (cs)
BR112014019291A2 (cs)
BR112014017588A2 (cs)
BR112014017618A2 (cs)
BR112014017647A2 (cs)
BR112014017623A2 (cs)
BR112014017630A2 (cs)
BR112014017652A2 (cs)
BR112014017631A2 (cs)
BR112014017627A2 (cs)